Her-2 is a well-researched tumor-associated antigen in cancer immunotherapy, given its widespread expression on various cancer cells, including medulloblastoma, osteosarcoma, glioblastoma, and breast cancer cells. This evidence concerns the gene ERBB2 and osteosarcoma.